Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Keymed BiosciencesFRA:64Z +0.64%49 Debt-to-Equity is 0.17 as of Jun. 2026, which is 325% above its 10-year median of 0.04. GuruFocus rates FRA:64Z with a GF Score™ of 49/100 and a GF Value™ of €16.65. The stock has 4 warning signs investors should review. Among 966 Biotechnology companies, Keymed Biosciences ranks worse than 51.24% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Keymed Biosciences's Debt-to-Equity or its related term are showing as below:
FRA:64Z'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.1 Med: 0.04 Max: 0.3
Current: 0.17
During the past 7 years, the highest Debt-to-Equity Ratio of Keymed Biosciences was 0.30. The lowest was -0.10. And the median was 0.04.
FRA:64Z's Debt-to-Equity is ranked worse than 51.24% of 966
companies
in the Biotechnology industry
Industry Median: 0.15
vs FRA:64Z: 0.17
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Keymed Biosciences Debt-to-Equity Related Terms
Keymed Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Keymed Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:64Z vs VRTX, REGN, MRNA: Debt-to-Equity Comparison
For the Biotechnology subindustry, Keymed Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Keymed Biosciences Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Keymed Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Keymed Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Keymed Biosciences (FRA:64Z) has a Debt-to-Equity of 0.17 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Keymed Biosciences and its competitors. This is 325% above median its historical median of 0.04. According to the industry distribution chart, Keymed Biosciences ranks #495 out of 966 companies in the Biotechnology industry, placing it in the top 51.2%.
Is Keymed Biosciences' Debt-to-Equity too high?
Keymed Biosciences' current Debt-to-Equity of 0.17 is 325% above median its 10-year median of 0.04. The Biotechnology industry median Debt-to-Equity is 0.15. Keymed Biosciences' value of 0.17 is 13.3% above this industry median. Based on the distribution chart, Keymed Biosciences ranks #495 out of 966 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Keymed Biosciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Keymed Biosciences' Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Keymed Biosciences ranks #495 out of 966 companies for Debt-to-Equity. This places Keymed Biosciences in the lower half of its industry. The industry median Debt-to-Equity is 0.15. Keymed Biosciences' value of 0.17 is 13.3% above this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.15, Keymed Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Keymed Biosciences's current Debt-to-Equity of 0.17 is 13.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Keymed Biosciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Keymed Biosciences's current Debt-to-Equity is 0.17, which is 325% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Keymed Biosciences stock overvalued right now?
Keymed Biosciences (FRA:64Z) has a current Debt-to-Equity of 0.17. The stock's GF Value™ is €16.65, compared to a current price of €7.90 — trading 52.6% below its estimated fair value. The current Debt-to-Equity is 0.17, which is 325% above median its 10-year median of 0.04 and 13.3% above the Biotechnology industry median of 0.15. Keymed Biosciences' overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Keymed Biosciences (FRA:64Z), the current Debt-to-Equity is 0.17 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Keymed Biosciences (FRA:64Z) Overvalued in 2026?
Based on GuruFocus' analysis, Keymed Biosciences stock appears to be undervalued.
The current stock price of €7.90 is trading 52.6% below its estimated GF Value™ of €16.65.
Key valuation signals for FRA:64Z:
Debt-to-Equity: 0.17 (325% above median its 10-year median of 0.04)
GF Value™: €16.65 vs. price of €7.90 (52.6% below fair value)
Industry Position: 13.3% above the Biotechnology median (#495 of 966)
No single metric tells the full story. See the FRA:64Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Keymed Biosciences Inc is a biotechnology company with multiple clinical-stage assets. The company is focused on the in-house discovery and development of biological therapies that address large underserved medical needs in the autoimmune and oncology therapeutic areas. Its clinical-stage drug candidates include CM310, CM326, CM313, and CM336 among others. The company is engaged in biopharmaceutical research and development, which is regarded as a single reportable segment. Geographically, it generates a majority of its revenue from overseas markets and the rest from Mainland China.
49GF Score
Get the complete analysis for FRA:64Z
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:64Z has been successfully added to your 
